University of Medicine and Dentistry of New Jersey

Rissmiller DJ, Campo T: Extended-Release BupropionInduced Grand Mal Seizures, Journal of the American Osteopath Associaton, 107: 441-442. . Vol. : (2007 ) .

Pinninti N, Rissmiller DJ, Steer RA, Beck AT: Severity of Self-Reported Depression in Patients with a Schizoaffective Disorder. Journal of Psychopathology and Behavioral Assessment, 28: 165 170 . . Vol. : (2006 ) .

Kumar G, Rissmiller DJ, Steer RA, Beck AT: Mean Beck Depression Inventory-II total score by type of bipolar episode. Psychological Reports 98: 836-840 . . Vol. : (2006 ) .

Rissmiller DJ, Rissmiller JH. Evolution of the Antipsychiatry Movement into Mental Health Consumerism. Psychiatric Services. 2006 Jun;57(6):863-6.. . Vol. : (2006 ) .

Rohatgi G, Rissmiller DJ: Treatment of Carisoprodol Dependence: A Case Report. Gorman JM: Case Discussion. Journal of Psychiatric Practice 11(5): 347-352, 2005 . . Vol. : (2005 ) .

Pinninti N., Musser, E., Madison, H., Rissmiller D.J. MINI International Neuropsychiatric Schedule: clinical utility and patient acceptance. Eur Psychiatry 18(7): 361-4, 2003. . Vol. : (2003 ) .

Pinninti N., Steer R.A., Rissmiller D.J., Nelson S., Beck A.T. Use of the Beck Scale for Suicidal Ideation with psychiatric inpatients diagnosed with schizophrenia, schizoaffective, or bipolar disorders. Behaviour Research and Therapy 40: 1071-79, 2002. . Vol. : (2002 ) .

Pinninti, NR., Rissmiller, D. Incidence of restraint-related deaths. Psychiatric Services 52 (7): 975, 2001. . . Vol. : (2001 ) .

Rissmiller, DJ., Madison, H., Pinninti, N. Update on Major Depression for Primary Care Physicians. The Journal New Jersey Association of Osteopathic Physicians & Surgeons (14): 6-13, 2001. . Vol. : (2001 ) .

Rissmiller, D.J., Musser, E., Rhoades, W., Rissmiller, F.R., Steer, R.A. A survey of use of a durable power of attorney to admit geropsychiatric patients. Psychiatric Services, 52: 98-100, 2001. . . Vol. : (2001 ) .

Steer RA, Rissmiller D.J., Beck AT: use of the Beck Depression Inventory-II with depressed geriatric inpatients. Behaviour Research and Therapy, 38: 311-318, 2000.. . Vol. : (2000 ) .

Rissmiller, D.J., Steer, R.A., Friedman, M., DeMercurio, R. Prevalence of Malingering in Suicidal Psychiatric Inpatients: A Replication. Psychological Reports, 84: 726-730, 1999.. . Vol. : (1999 ) .

Rissmiller, D.J., Wayslow, A., Madison, H., Hogate, P., Rissmiller, F.R., Steer, R.A: Prevalence of Malingering in inpatient suicide ideators and attempters. Crisis, l9(2): 62-66, 1998.. . Vol. : (1998 ) .

Rissmiller, D.J., Hogate, P.M., August, D., Zeltvay, N., Rissmiller, F., & Steer, R.A.: Commitment Decisions: Identification of indeterminate cases. Crisis, 15(3), 110-115, 1994.. . Vol. : (1994 ) .

Steer, R.A., Rissmiller, D.J., Ranieri, W.F., & Beck, A.T.: Use of the computer administered Beck Depression Inventory and Hopelessness Scale with psychiatric inpatients. Computers in Human Behavior, 10, 223-229, 1994.. . Vol. : (1994 ) .

Rissmiller, D.J., Steer, R.A., Ranieri, W.F., Rissmiller, F., & Hogate, P: Factors complicating cost containment in the treatment of suicidal patients. Hospital and Community Psychiatry (Now Psychiatric Services), 45, 782-788, 1994. . . Vol. : (1994 ) .

R.A. Steer, D.J. Rissmiller, W.F. Ranieri, A.T. Beck: Dimensions of Suicidal Ideation in Psychiatric Inpatients, Behav. Res. Ther. Vol. 31, No. 2, 229-236, 1993.. . Vol. : (1993 ) .

D.August,D.O., D. Rissmiller, D.O., N. Zeltvay, D.O.: Dilemmas in civil commitment, Journal of the American College of Neuropsychiatrists, 14-19, 1993.. . Vol. : (1993 ) .

R.A. Steer, Ed.D., D.J. Rissmiller, D.O., W.F. Ranieri, D.O.: Structure of computer assisted Beck Anxiety Inventory with Psychiatric Inpatients, Journal of Personality Assessment, 60(3) 532-542, 1993.. . Vol. : (1993 ) .

Top of page

Grants and Contracts

Title: "Computer-Assisted Psychiatric Interviewing to Improve the Validity and Reliability of DSM-III Axis II (Personality) Disorder Diagnosis,"
Sponsor: BSRG Grant
Effective Date(s): 6/85 - 3/86
Role: Principal Investigator

Title: Cognitive behavior therapy as adjunct to second-generation antipsychotics in treatment of schizophrenia.
Sponsor: The National Alliance for Research on Schizophrenia and Depression
Effective Date(s): 2005 - 2007
Role: Co-investigator

Title: Bifeprunox and Comparators Effect on Body Weight
Sponsor: Wyeth
Effective Date(s): 2006 - Ongoing
Role: Principal Investigator

Title: An 8-week, randomized, double-blind, fixed dosage, placebo-controlled, parallel-group, multi-center study of the efficacy, safety and tolerability of agomelatine 25 mg and 50 mg in the treatment of Major Depressive Disorder (MDD) followed by a 52-week, open-label extension.
Sponsor: Novartis
Effective Date(s): 2007 - Ongoing
Role: Principal Investigator

Title: Quetiapine Treatment for Symptoms Associated with Borderline Personality Disorder.
Sponsor: Supported by Astra Zeneca
Effective Date(s): 2005 - Ongoing
Role: Prinicipal Investigator

Title: A multi-Center Randomized Placebo-Controlled Double Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Dose Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia.
Sponsor: AstraZeneca
Effective Date(s): 2007 - Ongoing
Role: Principal Investigator

Title: A Multicenter, Double-Blind, Study on the Efficacy and Safety of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With a Recent Manic or Mixed Episode
Sponsor: Bristol Myers Squibb
Effective Date(s): 2006 - Ongoing
Role: Principal Investigator

Title: A 52-Week Multi-centre, Double-blind, Randomized, Withdrawal, Parallel-group, Placebo-controlled, Phase III Study of the Efficacy (Time to Event) and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) 50, 150, 300 mg/day as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder
Sponsor: Astra Zeneca
Effective Date(s): 2006 - Ongoing
Role: Prinicipal Investigator

Title: Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized Double-Blind Comparison with Placebo.
Sponsor: Eli Lilly and Company
Effective Date(s): 2003 - 2004
Role: Principal Investigator

Title: A multicenter, open-label, flexible-dose, parallel-group evaluation of the cataractogenic potential of quetiapine fumarate (SEROQUEL) and risperidone (RISPERDAL) in the long-term treatment of patients with schizophrenia or schizoaffective disorder.
Sponsor: AstraZeneca
Effective Date(s): 2003 - 2006
Role: Principal Investigator

Top of page